CIMON

MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, AP-HP, Bone marrow, Survival, Immunotherapy, Patient, Innovation, IND, Ipilimumab, European Medicines Agency, Therapy, Artificial intelligence, Charcot disease, ASH, EMA, Head, MET, Investigational New Drug, Nivolumab, Safety, SITC, Microbiome, Food, ODD, Development, Acceleration, Maat, ARES, Cancer, AACR, DSMB, Haematopoietic system, Annual general meeting, OS, EUR, Physician, CIMON, CGMP, EAP, EBMT, ICI, Society, Randomized controlled trial, Symantec Endpoint Protection, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported the full-year 2023 annual results and provided a business overview.
  • In December 2023 , the Company presented positive results from the Early Access Program (EAP) in Europe involving 111 patients with aGvHD treated with MaaT013, at the 2023 American Society of Hematology (ASH) Annual Meeting.
  • In April 2023 , data from the Phase 1b study (CIMON) with MaaT033, previously communicated during the 64th annual ASH meeting, were also presented at the EBMT 2023 conference.
  • During 2023 and Q1 2024, MaaT Pharma reinforced its board of directors, executive team, and key functions:
    Karim Dabbagh as Chairman and Nadia Kamal as Director, both independent.

MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Partnership, CIMON, ASH, ICI, DSMB, Head, European Medicines Agency, Survival, Charcot disease, Clinical trial, Cancer, SITC, Immunotherapy, Maat, EMA, Development, ARES, Investigational New Drug, PICASSO, Patient, CGMP, Microbiome, Lifting, MET, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, IND, Food, Pharmaceutical industry, Nursing, Rare-earth element, Management, HSCT, Alexis de Tocqueville, ALS

Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.

Key Points: 
  • Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.
  • In June 2023 , MaaT Pharma also announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced joining the Microbiome Therapeutics Innovation Group (MTIG).
  • The key unaudited financial results for the first half of 2023 are as follows:

MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, EBMT, IPO, EAP, CIMON, Failure, ICI, ASH, DSMB, Head, Charcot disease, Survival, Cancer, AGM, Research, American Society of Hematology, Maat, EMA, EUR, ARES, Science, Investigational New Drug, PICASSO, Patient, European, Microbiome, MET, Knowledge, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, ORR, Food, Pharmaceutical industry, Management, Lists of plant diseases, ALS

"As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.

Key Points: 
  • "As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.
  • In June 2023 , MaaT Pharma announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced having joined the Microbiome Therapeutics Innovation Group (MTIG).
  • MaaT Pharma reported revenues2 from its compassionate access program of EUR 0.7 million for the quarter ended June 30, 2023, comparable with EUR 0.7 million for the first quarter of 2023.

MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview

Retrieved on: 
Thursday, March 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Partnership, CIMON, ICI, Therapy, DSMB, Clinical trial, Bone marrow, Maat, Acute myeloid leukemia, ARES, AP-HP, CGMP, Patient, Agency, Data, Drug development, Ecosystem, FDA, Letter, Medi-Cal Access Program, Conference, ANSM, Pharmaceutical industry, Clothing, ALS

Cash inflows from financing reflects new financial debt, offset by debt repayments over 2022 €1.9 million.

Key Points: 
  • Cash inflows from financing reflects new financial debt, offset by debt repayments over 2022 €1.9 million.
  • Total financial debt (including lease liabilities) totaled €11.4 million as of December 31, 2022, of which €0.9 million relates to state-backed loans (“PGE”).
  • The communication from the FDA therefore provides a path forward regarding MaaT Pharma’s pooling technology for this trial.
  • The Company’s universal registration document, which includes the annual financial report, will be available on MaaT Pharma’s website: www.maatpharma.com
    *Indicative calendar that may be subject to change.

MaaT Pharma Reports Cash and Revenues for Third Quarter 2022

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Kepler, Euronext Paris, Achievement, ANSM, Company, Digital, Society, IHMC, Maat, ARES, Agence nationale de sécurité du médicament et des produits de santé, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Salvage therapy, EUR, Drug design, IPO, Congress, EST, CGMP, Graft-versus-host disease, Survival, Forward-looking statement, Conference, Special access program, LSX, Annual general meeting, PICASSO, FDA, Biomarker, CIMON, Communication, Drug, ASH, R, Safety, CEO, Food, Showcase, EAP, Patient, Cancer, MET, Lymphatic system, CIC, UCSD Student-Run Free Clinic Project, Acute myeloid leukemia, International, Pharmaceutical industry, Film, Fine chemical

MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.
  • The net increase in cash over the third quarter of 2022 was EUR 1.9 million.
  • November 15-17, 2022 13th Annual Jefferies London Healthcare Conference London, UK: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Carole Schwintner, Chief Technology Officer of MaaT Pharma will attend the conference.
  • November 29, 2022 Investir day Paris, France: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Savita Bernal, Chief Business Officer of MaaT Pharma will attend the investor event.

MaaT Pharma Publishes its Half Year Results and Provides a Business Overview

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICI, Therapy, Global, Safety, CIC, FDA, Food, Biomarker, PICASSO, CGMP, Association, Maat, Company, Growth, Partnership, Achievement, Forward-looking statement, Patient, Clinical trial, Market Access Program, Hematopoietic stem cell transplantation, BNP Paribas, Ecosystem, ARES, Lymphatic system, Research, Graft-versus-host disease, R, Operating cost, Communication, CIMON, CERA, Euronext Paris, AP-HP, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Fine chemical, Caisse, Euronext

Operating loss amounted to 7.4 million compared with 4.0 million in the first half of 2021, an increase of 3.4 million.

Key Points: 
  • Operating loss amounted to 7.4 million compared with 4.0 million in the first half of 2021, an increase of 3.4 million.
  • The trial is sponsored by AP-HP with MaaT Pharma supplying drug candidates and performing the microbiome profiling of patients using its proprietary gutPrint platform.
  • A second down payment was made to Skyepharma by the Company in the first half of 2022.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, OTU, Life, Lymphatic system, CIMON, Biomarker, Prognosis, Achievement, Company, Sorbonne University, Program, Science, Graft-versus-host disease, Euronext Paris, IPO, European Medicines Agency, Survival, University of Toulouse, 16S, Forward-looking statement, CEO, Immunity, AML, Dysbiosis, Otus, AE, Gastroenteritis, MET, Hematopoietic stem cell transplantation, Patient, Acute myeloid leukemia, Immune system, SAE, CGMP, Population, Hospital, Infection, Operational taxonomic unit, Bacteria, Principal, AP-HP, Scientific Advice Mechanism, Hematology, Capsule, Cancer, Safety, HRMS, Pharmaceutical industry

The topline results also show rapid and persistent engraftment of MaaT033 in the patients gut.

Key Points: 
  • The topline results also show rapid and persistent engraftment of MaaT033 in the patients gut.
  • Todays announcement confirms previously-announced promising interim results of the trial, which allowed early completion of the study.
  • Together with a good safety profile, this solid evidence for our first oral candidate is a crucial milestone for MaaT Pharma, commented Herv Affagard, CEO and co-founder of MaaT Pharma.
  • This strong foundational data supports the launch of the next phase evaluating MaaT033 in preventing allo-HSCT complications in this patient population.

MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview

Retrieved on: 
Thursday, April 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Kepler, ARES, MET, Population, Use, Research, Nivolumab, Patient, Biomarker, Forward-looking statement, Kepler Cheuvreux, Atun, Acute myeloid leukemia, Business, Graft-versus-host disease, Ipilimumab, AP-HP, Society, Achievement, CIMON, Conference, Company, CGMP, EAP, Partnership, IPO, Technical, Legislation, R, Market Access Program, Degenerative disease, Growth, AML, Safety, Cancer, ICI, Medical Affairs Bureau, CMO, ASH, Pharmaceutical industry, Healthcare, Security (finance), Fine chemical, Euronext Paris, Euronext

Average annual employees evolved from 24 in 2020 to 33 in 2021 following the strengthening of the Medical Affairs team, along with the R&D and Technical departments as well as Business development.

Key Points: 
  • Average annual employees evolved from 24 in 2020 to 33 in 2021 following the strengthening of the Medical Affairs team, along with the R&D and Technical departments as well as Business development.
  • Dr John Weinberg, CMO, has resigned from his position to pursue other activities and will leave the Company in early May.
  • March 2021: Release of positive topline results for Phase 2 trial evaluating MaaT013 in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.
  • MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

Retrieved on: 
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biomarker, Euronext Paris, Survival, Forward-looking statement, Patient, Human, Degenerative disease, Safety, Incidence, MET, CIMON, OTU, Operational taxonomic unit, Maat, CEO, Data monitoring committee, Acute myeloid leukemia, Bacteria, Graft-versus-host disease, Enema, Company, 16S, CGMP, MD, Capsule, Cancer, Pharmaceutical industry, Dietary supplement, Antibiotics, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA

Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.

Key Points: 
  • Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
  • These interim results are an important milestone for MaaT Pharma as MaaT033 is our second drug candidate and our first oral formulation, to demonstrate proof of engraftment in humans, said Herv Affagard, CEO and co-founder of MaaT Pharma.
  • MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
  • We look forward to further exploring the data from CIMON and preparing for a Phase 2/3 trial start.